{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"condition":["RAS mutant colorectal cancer"],"disease":["Ras Mutant Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2726186"],"location":["China"],"study_start_month":["8"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"An exploratory clinical study of fluzoparib combined with bevacizumab in the maintenance treatment of RAS mutant colorectal cancer after first-line chemotherapy","description":"Interventions: Experimental group:fluzoparib combined with bevacizumab\nPrimary outcome(s): Progression-free survival\nStudy Design: Single arm","dates":{"creation":"2021-08-15"},"accession":"2726186","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2100050106"]}}